

## **PUBLIC WORKSHOP**

Methodological aspects of biomarker discovery and validation: BIOMARGIN as a case study

Organised by the BioMargin Consortium

February 21st 2017



BioPark 11 Rue Watt Paris, France

## **PROGRAMME**





10h10	Registration
101110	Welcome Coffee
10h20	Welcome by Pierre Marquet, scientific coordinator of the BioMargin Consortium
10h30 - 11h40 Session I — Methodology of clinical studies and levels of evidence of biomarkers	
(Chair: Marie Essig)	
10h30 – 10h50	Wilfried Gwinner, University of Hanover, Germany
10h50 – 11h20	Challenges in the assessment of the transplant  Petra Reinke, Charité, Germany
	Methodological and clinical aspects/issues of BIODRIM
441.20 441.40	Pierre Marquet, Inserm, France
11h20 – 11h40	BioMargin Design and expected evidence of the outcomes
11h40 - 13h00 Session II – Nucleic acids as biomarkers: technical aspects and constraints	
(Chair: Joost Schanstra)	
11h40 – 12h10	Ekkehard Schütz, Chronix Biomedical, Germany
	Methodological considerations about cell-free DNA as a source of biomarkers
12h10 – 12h30	Maarten Naesens, KULeuven, Belgium  Profiling and validation of mRNA biomarkers in blood and biopsies
12h30 – 12h50	Dany Anglicheau, Hôpital Necker, France
	Methodological issues of miRNA profiling and validation of miRNA biomarkers in different
	matrices
12h50 - 14h00 Lunch	
14H00 - 17H00 Session III – Mass spectrometry for proteomic and metabolomics biomarkers: methodology	
and clinical transfer	
(Chair: Maaı	rten Naesens)
14h00 – 14h30	Vladimír Havlíček, Academy of Sciences of the Czech Republic, Czech Republic
	From MSI to REIMS: meet interesting abbreviations in clinical mass spectrometry
14h30 – 15h00	Anna Baud, UCL IRIS, UK Protein biomarker discovery for translation to the clinic
15h20 – 15h40	Inge Mertens, VITO, Belgium
	Mass spectrometry based clinical proteomics as a tool for liquid biopsy biomarker
	discovery
15h40 – 16h00	Jochen Metzger, MOS, Germany
	Capillary electrophoresis-mass spectrometry for clinical diagnosis – A commercialization model based on proprietary methodology rather than a patented test
16h00 - 16h30	Coffee Break
	Short oral presentations:  Endogenous metabolic profiling as a fundament in personalized theranostics
16h30 – 17h00	Torbjörn lundstedt, AcureOmics, Sweden
1555 171105	The SWATH mass spectrometry technology as applied to urine peptidomics
	François- Ludovic Sauvage, Inserm, France
17H00	End of meeting



